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Abstract
Long-term administration of acetylsalicylic acid (ASA) was effective in prevention of colorec-
tal cancer, whereas the efficacy of this compound in other cancer types, including breast
cancer, has been less convincingly documented. Indeed, the antimetastatic effect of low-
dose ASA was observed only in the early intravascular phase of metastasis of breast can-
cer. In the present work, we characterized the effects of long-term treatment with ASA on
the late phase of pulmonary metastasis in a mouse orthotopic 4T1 breast cancer model.
Mice were treated with ASA at a dose of 12 mg�kg-1 of body weight daily starting one week
prior to inoculation of 4T1 breast cancer cells, and the treatment was continued throughout
progression of the disease. ASA administration decreased platelet TXB2 production in ex
vivo assays but did not change thrombin-induced platelet reactivity. Although the number of
metastases in the lungs remained unchanged in ASA-treated mice, infiltration of inflamma-
tory cells was increased concomitantly with higher G-CSF and serotonin concentrations in
the lungs. Pulmonary NO production was compromised compared to control 4T1 mice. ASA
treatment also evoked an increase in platelet and granulocyte counts and decreased sys-
temic NO bioavailability along with increased markers of systemic oxidant stress such as
higher GSSG/lower GSH concentrations in RBC. Analysis of eicosanoids in stirred blood
demonstrated that administration of ASA at a dose of 12 mg�kg-1 to cancer-bearing mice
had an effect beyond inhibition of platelet COX-1, suggesting long-term treatment with low-
dose aspirin is not a selective murine platelet COX-1/TXA2 pathway inhibitor in cancer-bear-
ing mice. In summary, quite surprisingly, long-term treatment with low-dose ASA adminis-
tered until the advanced phase of breast cancer in a murine orthotopic model of 4T1 breast
cancer negatively affected the phenotype of the disease.
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Introduction
Acetylsalicylic acid (ASA) has been intensively studied over the last few decades with respect
to its anti-metastatic effects. While at high doses ASA inhibits both isoforms of cyclooxygenase
(COX-1 and COX-2) and has anti-proliferative/pro-apoptotic effects with respect to cancer
cells, anti-metastatic effects of lower doses of ASA (�100 mg�kg-1 per day in humans equiva-
lent to�15 mg�kg-1 in mice [1]) are attributed to the inhibition of COX-1 and thromboxane
A2 (TXA2) synthesis by platelets [2]. Indeed, a vast number of platelet-dependent mechanisms
involved in cancer progression and metastasis have been identified [3]. Furthermore, in case
studies and metanalysis of randomized clinical trials (where effects of ASA were examined in
entities not related to cancer), it was documented that ASA used at low anti-platelet dose
reduced primary cancer and metastasis incidence [4–7], however the effects were not con-
firmed in the elderly people [8]. Surprisingly, higher all-cause mortality was observed among
initially healthy older adults who received daily aspirin than among those who received pla-
cebo and it was attributed primarily to cancer-related death [8]. Moreover, in particular types
of cancer, the positive effects of ASA were also not so evident [9]. While ASA consistently low-
ered the incidence of gastrointestinal cancers (i.e. colorectal) [4] and is now recommended for
primary prevention of colorectal cancer in adults older than 76 years [10], the evidence for the
efficacy of ASA in breast cancer patients is less convincing, with some reports supporting the
anti-metastatic activity [11], and others showing no evident reduction of both the risk [12, 13]
and the number of deaths [6]. Therefore, there is an on-going ADD-ASPIRIN Trial [14]
devoted to the potential use of ASA as an agent inhibiting post-surgery metastasis in cancer
(including breast) patients, that will provide an important re-evaluation of and the anti-meta-
static effects of aspirin, but the results have not yet been published.
In this context, many questions still need to be answered including the dosage, duration of
use and optimal timing for initiation of the therapy with ASA to achieve the anticancer effects
in various types of malignancies, in particular non-gastrointestinal ones [11]. Indeed, it has
been recently shown that ASA-dependent inhibition of COX-1/TXA2 pathway in platelets
effectively lowered metastatic spread of breast cancer only when applied in the early phase dur-
ing formation of an intravascular metastatic niche, but anti-metastatic effects of the same dose
were not observed when ASA was administered during the extravascular phase of metastasis
[15].
To characterise the therapeutic efficacy of long-term treatment of ASA in breast cancer, we
studied the effects of low-dose ASA (12 mg�kg-1) on disease progression and metastasis in an
orthotopic murine model of breast cancer when therapy was initiated seven days prior to inoc-
ulation of 4T1 breast cancer cells, and continued throughout the progression of the disease,
until its advanced stage. Our results clearly demonstrated that chronic use of ASA at such a
dose and schedule of administration negatively affected the phenotype of the disease.
Materials and methods
Animals
Female BALB/c mice (aged 7–11 weeks) were purchased from the Medical University of Bialy-
stok (Poland) and were housed 5–6 per cage, in a temperature-controlled environment (22–
25˚C), 12-hour light/day cycle and unlimited access to food (Zoolab, Krakow, Poland) and
water throughout the experiment.
ASA administration to breast cancer-bearing mice. Fifty mice were randomly divided into
control non-ASA-treated (4T1 group, 25 mice) and mice treated with ASA (4T1+ASA, 25
mice) (acetylsalicylic acid (Sigma Aldrich, A5376) premixed with chow) at a dose of ~12 mg
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per kg of body weight per 24 h that is equivalent to ~100 mg per 24 h in a 70 kg-human [1].
ASA treatment was started seven days prior to orthotopic inoculation of 4T1 breast cancer
cells. All mice from control 4T1 and 4T1+ASA groups were orthotopically inoculated with
1x104 of 4T1-luc2td-Tomato cells and all animals were euthanised in the 5th terminal week of
the disease progression by i.p. injection of ketamine and xylazine, 100 and 10 mg�kg-1, respec-
tively. All experimental procedures involving animals performed to obtain the data presented
in this study were specifically accepted by the Second Local Ethical Committee on Animal
Testing in the Institute of Pharmacology, Polish Academy of Sciences (Krakow, Poland), per-
mit no: 97/2016. Since orthotopic inoculation of cancer cells into the mammary fat pad of
mice was not associated with animal distress higher than performing a subcutaneous injection
(cancer cells were introduced in 50μl suspension by subcutaneous injection in the mammary
fat pad), no anaesthesia was administered during this procedure according to the approval of
the Second Local Ethical Committee on Animal Testing. Mice welfare was monitored through-
out the study once daily and mice were euthanised (i.p. injection of ketamine and xylazine,
100 and 10 mg�kg-1, respectively) in case of evident (1) isolation of the animal from the group,
and (2) evident (>20%) body weight loss.
Cell culture
The mouse mammary adenocarcinoma 4T1-luc2-tdTomato cell line (in short: 4T1 cells) stably
expressing the firefly luciferase gene and tdTomato fluorescent protein was a kind gift of Pro-
fessor Joanna Wietrzyk (Ludwik Hirszfeld Institute of Immunology and Experimental Ther-
apy, Polish Academy of Sciences) in 2015 at the 5th passage from resuscitation after their
purchase from Caliper Life Sciences Inc. (USA)) (the source of the parental line: ATCC, CRL-
2539). The 4T1 cells were authenticated by Caliper Life Sciences Inc. by measurement of lucif-
erase and tdTomato expression using an IVIS Spectrum Bioluminescence (BLI) and Fluores-
cence Activity (FLI). 4T1-luc2-tdTomato cells were cultured in RPMI1640 GlutaMAX
Medium (Gibco) supplemented with 10% FBS (Gibco), antibiotic antimycotic solution, (AAS,
Sigma-Aldrich) containing 20 units of penicillin, 20 mg of streptomycin and 0.05 mg of
amphotericin B. Cells were cultured at 37˚C in an atmosphere of 5% CO2 as previously
described [16]. Prior to transplantations, cells were detached using Accutase solution (Sigma-
Aldrich, Poland), centrifuged (300 x g, 4˚C, 5 min), counted, suspended in Hank’s Balanced
Salt Solution (HBSS, IIET, Poland) and inoculated into the mammary gland of female BALB/C
mice. All cell cultures were routinely tested for Mycoplasma contamination.
Blood collection
Blood was collected from the right heart ventricle on 3.8% citrate (9:1 v/v) and used for mea-
surement of blood count, eicosanoid profile and platelet reactivity or centrifuged at 4˚C at
1000 x g for 10 min to obtain plasma that was aliquoted and frozen at -80˚C for subsequent
analysis.
Growth of primary tumour, pulmonary metastasis and lung airness
After euthanasia, primary tumours and lungs were excised and weighed. Lungs were fixed in
4% buffered formalin solution to assess pulmonary metastasis. The number of secondary nod-
ules in the lungs was counted on the surface of lung lobes under a magnifying glass and on
lung cross-sections stained with haematoxilin and eosin (H&E). Concomitantly, the relative
metastatic area was measured and presented as the percentage of the cross-section area of the
lung lobes. For assessment of relative lung nuclei area, ten randomly chosen eye fields of H&E
stained lungs cross-sections were photographed by a blinded investigator with the exclusion of
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lung metastases as well as larger lung alveoli and segmented in Ilastik (developed by the Ilastik
team, with partial financial support by the Heidelberg Collaboratory for Image Processing,
HHMI Janelia Farm Research Campus and Cell Networks Excellence Cluster). The relative
number of pixels corresponding to the area of the lung cross-sections occupied by the capillar-
ies and other cells and nuclei of the cells in the lung parenchyma were counted in each experi-
mental group using Image J [17].
NO production
Colloidal Fe(DETC)2 was used for trapping the intracellular NO production in the lungs with
EPR detection as described previously in mouse models of 4T1 breast cancer [16] and endotox-
emia [18]. Briefly, lungs were perfused with ice-cold PBS, excised and cut into small pieces and
incubated for 90 minutes at 37˚C in colloidal Fe(DETC)2 in Krebs-HEPES buffer. Measurement
of Fe(DETC)2-NO signal in frozen samples was performed in a finger Dewar using an EMX
Plus Bruker spectrometer and the NO triplet amplitude normalised to wet tissue weight.
Measurement of GSH and GSSG concentration by capillary electrophoresis
Capillary electrophoresis. A P/ACE MDQ capillary electrophoresis system (Beckman
Coulter, Fullerton, CA, USA) with 32 Karat software (ver. 8.0, Beckman Coulter, Fullerton,
CA, USA) was used for analyses. The apparatus was equipped with a PDA detector set at λ =
200 nm. Separation of the analytes took place in an uncoated fused-silica capillary (60.2 cm
total length, 50 cm effective length, 50 μm i.d. and 375 μm o.d.) thermostated at 25˚C with a
constant voltage of 25 kV (~6.5 μA). BisTRIS (75 mmol/L), boric acid (25 mmol/L) buffer
adjusted to pH 7.8 by adding 1 mol/L NaOH, was chosen as a background electrolyte (BGE).
Samples were introduced to the capillary by hydrodynamic injection for 20 sec by 3.5 kPa, fol-
lowed by injection of dd H2O for 2 sec by 3.5 kPa. Between analytical runs, the capillary was
rinsed with 1 mol/L NaOH, deionised water, and BGE, respectively (138 kPa; 2 min each).
Obtained data were analysed by PeakFit software (ver. 4.12, Systat software, San Jose, CA,
USA).
Sample preparation. Measurements of GSSG and GSH were performed as described by
[19]. Briefly, red blood cells (RBCs) were first separated from plasma by centrifuging whole
blood. A hemolysate was prepared by adding to 100 μl of RBC, 400 μl of haemolysing reagent
(10 mmol/L KCN and 5 mmol/L EDTA in dd H2O). Then, samples were deproteinised by add-
ing 100 μl of 5% metaphosphoric acid (MPA) to 100 μl of hemolysate. After centrifugation
(10,000 × g for 10 min at 4˚C), the MPA extracts were diluted 1:4 with dd H2O. The calibration
curves for GSH (2.5–80 μmol/L) and GSSG (0.5–16 μmol/L) were prepared by diluting the
stock solutions with 0.5% MPA. All chemicals except boric acid (J.T. Baker) and NaOH
(VWR) were purchased from Sigma Aldrich.
Measurement of blood count, NO metabolites and basal TXB2 in plasma,
G-CSF and serotonin concentrations in plasma and lung homogenates
Blood count was measured with an animal blood counter scil Vet abc (Horiba Medical,
France). Concentrations of NO metabolites (NO2
- and NO3
-) in plasma were measured with
an ENO-20 NOx Analyzer (Eicom Corp., Kyoto, Japan). Basal TXB2, G-CSF and serotonin
concentrations in plasma were determined with ELISA kits (Enzo Life Sciences, ADI-900-002;
Thermo Scientific, EMCSF3 and Enzo, ADI-900-175, respectively). For determination of
G-CSF and serotonin concentration, lung samples were homogenised in the buffer as previ-
ously reported [20] with some modifications and concentrations being measured with the
commercially available kits listed above and normalised to total protein measured with BCA.
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Measurement of eicosanoid production by LC-MS/MS
Sample preparation. Blood samples were diluted with saline (5 times) and stirred in alter-
nating directions in 1ml cuvettes with disposable, siliconised stir bars (Chrono-Log, US) for
one hour at 37˚C (1,500 rpm; spinning time in one direction: 3 s; acceleration/deceleration:
20,000 rpm�s-1) in a specially designed Xyzyk apparatus (Xyzyk Co, Poland), as described pre-
viously [21]. To determine the generation of eicosanoids ex vivo in the stirred blood, samples
were taken on aspirin (500 μM) after 60 minutes of ex vivo stirring in Xyzyk apparatus and
centrifuged to obtain plasma (3000xg, 12 min, 4˚C). All plasma samples were stored at -80˚C
for further eicosanoid analysis including TXB2, 6-keto-PGF1α, PGE2, PGD2, PGF2α, 8,9-,
11,12- and 14,15-EETs, 5-, 12-, 15-, 19- and 20-HETEs.
Urine samples after collection were clarified by centrifugation and kept at -80˚C for analysis
of TXA2 stable metabolite (2,3-dinor TXB2). The concentration of 2,3-dinor TXB2 was nor-
malised to creatinine level.
Plasma and urine samples were prepared for the LC-MS/MS assay according to the protocol
slightly changed from that previously described in [22, 23]. Briefly, after the addition of inter-
nal standard mixture, all samples were purified applying liquid-liquid extraction using acidi-
fied ethyl acetate. After the evaporation of organic layer, the dry residues were reconstituted in
ethanol and samples were directly injected into LC-MS/MS system.
Calibration and quality control samples were prepared using artificial plasma or urine [22,
23] spiked with known concentration of eicosanoid working standard solutions and extracted
according to the same procedure applied for the biological samples.
LC-MS/MS conditions and eicosanoid quantification. The LC-MS/MS system applied
for eicosanoid quantification consisted of a UFLC Nexera liquid chromatograph (Shimadzu,
Kyoto, Japan) and triple-quadrupole mass spectrometer Qtrap 5500 (Sciex, Framingham,
Maryland, USA) equipped with electrospray ion source.
The chromatographic separation of eicosanoids was achieved applying an Acquity UPLC
BEH C18 (3.0x100 mm, 1.7 μm, Waters, Milford, Massachusetts, USA) analytical column. The
mobile phases were delivered in gradient elution mode and consisted of 0.1% FA in ACN and
0.1% FA in H2O for plasma sample analysis and ACN and H2O+0.1%NH4OH for urine sam-
ple assay. The data acquisition was carried out in multiple reaction monitoring mode (MRM)
in the negative polarisation mode for all eicosanoids (TXB2, 6-keto-PGF1α, PGE2, PGD2,
PGF2α, 8,9-, 11,12- and 14,15-EETs, 5-, 12-, 15-, 19- and 20-HETEs, 2,3-dinor TXB2) and their
deuterated internal standards (TXB2-d4, 6-keto-PGF1α-d4, PGE2-d4, PGD2-d4, PGF2α-d4,
14,15-EET-d11, 5-HETE-d8, 12-HETE-d8, 15-HETE-d8, 20-HETE-d6, 2,3-dinor TXB2-d9).
The most specific and abundant ion transitions (Q1!Q3) for all measured eicosanoids and
their internal standards were thoroughly selected and used for quantification. The calibration
curves were plotted as the relationship between the peak area ratios of analyte/internal stan-
dard to the nominal concentration of the analyte. Eicosanoid levels in plasma and urine sam-
ples were calculated based on the regression equations estimated for each analyte. The LC-MS/
MS-based methods applied for eicosanoid quantification were validated and previously
described [22, 23].
Eicosanoid standards and their deuterated internal standards were bought from Cayman
Chemical.
Measurement of platelet activation by flow cytometry
Blood samples were diluted with saline and washed with Tyrode buffer. Each sample was dou-
ble stained with four-antibody panels from Emfret Analytics used at final dilution of 1:8. All
staining panels included platelet-specific antigen GpIIbIIIa (CD41/61), either FITC (cat no
PLOS ONE Aspirin affects late phase of mouse breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0230520 April 6, 2020 5 / 19
M025-1, monoclonal (clone Leo.F2), rat (Wistar) IgG2a) or PE (cat no M025-2, monoclonal
(clone Leo.F2), rat (Wistar) IgG2a)-conjugated, for platelet identification and one of four
platelet activation markers: PE-conjugated active form of GPIIb/IIIa (cat no M023-2, mono-
clonal (clone JON/A), rat IgG2b) and P-selectin (cat no M130-2, monoclonal (clone Wug.E9),
rat (Wistar) IgG1) antibodies; FITC-conjugated fibrinogen (cat no P140-1, rabbit polyclonal
IgG) or von Willebrand (vWF) factor–representing platelet binding capacity (cat no P150-1,
rabbit polyclonal IgG). Platelets were identified based on their forward- and side-scatter char-
acteristics and were gated on the basis of the expression of platelet-specific antigen CD41/61 as
shown previously [16]. Isotype control antibodies either FITC- (cat no P190-1, rat polyclonal
IgG) or PE (cat no P190-2, rat polyclonal IgG) -conjugated were used to assess non-specific
binding for each individual sample. Basal, ADP (20 μM) and thrombin (0.025 U�ml-1)-induced
activation of platelets was assessed on the basis of the measured expressions/binding level of
surface membrane antigens expressed as the percentage of all platelets above the isotype con-
trol fluorescent signal and the median fluorescence intensity (MFI). Flow cytometric analyses
of platelet activation was performed using flow cytometry software (LSRII and FACS/Diva ver.
6.0, respectively, Becton Dickinson, Oxford, UK). Measurements were made on a logarithmic
scale and at least 10 000 events were collected. Appropriate colour compensation was deter-
mined in samples singly stained with either FITC-conjugated anti-CD41/61 or PE-conjugated
anti-CD41/61.
Statistical analysis
Statistical significance was assessed in GraphPad Prism 5.03 with a parametric unpaired two-
sided T test or non-parametric Mann-Whitney test based on the normality of the data distribu-
tion (tested with a Shapiro-Wilk normality test), homogeneity of variances (tested with F test)
and the variable scale. The data were presented as mean ± SD or median of the data and inter-
quartile range (IQR) (from lower [25%] to upper [75%] quartile). Only P values�0.05 were
considered significant.
Results
Effects of long-term ASA treatment on systemic eicosanoid production and
platelet reactivity in breast cancer-bearing mice
ASA treatment exerted anti-platelet effects (Fig 1A); however, these effects were only observed
in ex vivo assays of the TXB2 generation in stirred blood (1.7±1.0x107 pg�ml-1�106 PLT in the
blood of breast 4T1 cancer-bearing mice vs 1.0±0.6x107 pg�ml-1�106 PLT in the blood of breast
cancer-bearing mice treated with ASA (4T1+ASA), P = 0.0219) (Fig 1A), whereas basal TXB2
plasma concentration (Fig 1B) as well as 2,3-dinor-TXB2 concentration in urine (Fig 1C) were
not changed. The production of other prostanoids (6-keto-PGF1α (stable metabolite of PGI2),
PGE2, PGD2 and PGF2α) (Fig 2A–2D) in the stirred blood was not altered between 4T1 and
4T1+ASA groups. However, ASA treatment resulted in a substantial decrease of 11,12-EET
and 14,15-EET generation, causing a decrease in their concentration below the limit of quanti-
fication of the applied LC-MS/MS method in the majority of the samples (185.3; 119.6–242.3
pg�ml-1 for 4T1 vs<50.0 pg�ml-1 for 4T1+ASA group, P = 0.0010 and 291.7; 259.3–392.1
pg�ml-1 for 4T1 vs<25.0 pg�ml-1 for 4T1+ASA group, P = 0.0033, respectively) (Fig 2F and
2G). The level of 5-, 12- and 15-HETE was unchanged and independent of ASA administration
(Fig 2H–2J), whereas the production of 19-HETE was increased in the stirred blood of ASA-
treated cancer-bearing mice (4,980.0; 4,390.0–8200.0 pg�ml-1 for 4T1 vs 9,200.0; 7,875.0–
10,725.0 pg�ml-1 for 4T1+ASA group, P = 0.0335) (Fig 2K) concomitantly with 20-HETE
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(1,720.0; 1,283.0–1,740.0 pg�ml-1 for 4T1 vs 5,200.0; 3,840.0–6,750.0 pg�ml-1 for the 4T1+ASA
group, P = 0.0052) (Fig 2L). Surprisingly, ASA treatment had little effect on basal, ADP and
thrombin-induced PLT reactivity as assessed by flow cytometry (Fig 3A–3H).
Effects of long-term ASA treatment on breast cancer progression and blood
count of cancer-bearing mice
The number of pulmonary metastases, relative pulmonary metastatic area and primary tumour
weight were not affected in the 4T1+ASA group as compared with the 4T1 group (Table 1).
Intriguingly, the weight of the lungs was higher in breast cancer-bearing mice treated with
ASA. These results stayed in line with reduced lung airness, increased area occupied by cell
nuclei in the lung parenchyma and higher number of circulating granulocytes in response to
ASA treatment of cancer-bearing mice (Table 1). There was also an increase in platelet count
(PLT) as well as higher absolute neutrophil count (ANC) and absolute neutrophil to absolute
lymphocyte ratio (NLR) in mice from the 4T1+ASA group vs the control 4T1 group (Table 1).
The representative images of pulmonary metastases in 4T1 and 4T1+ASA group of mice are
shown in Fig 4).
Effects of long-term ASA treatment on G-CSF and serotonin
concentrations in breast cancer-bearing mice
In line with more pronounced infiltration of the lung parenchyma of 4T1+ASA group of mice
by inflammatory cells as evidenced by increased nuclei area in the lungs (Table 1), the concen-
tration of granulocyte-colony stimulating factor (G-CSF) was increased in lung homogenates
of the 4T1+ASA group as compared to the 4T1 group (316.3±106.1 pg�ml-1 μg of protein-1 vs
187.7±76.9 pg�ml-1 μg of protein-1, respectively, P = 0.0046) (Fig 5A). Similarly, the concentra-
tion of serotonin (related to pro-inflammatory environment in the lungs [24]) was also higher
in the lung homogenates of 4T1+ASA mice (28.4±19.0 ng�ml-1 μg of protein-1 vs 10.0±3.1
ng�ml-1 μg of protein-1 in 4T1 group, P = 0.0100) (Fig 5B). In contrast to the lungs, there was
no difference in G-CSF and serotonin concentrations in the plasma (Fig 5C and 5D).
Effects of long-term ASA treatment on NO production in the lungs and
systemic NO bioavailability in the plasma of breast cancer-bearing mice
In the metastatic lungs of the 4T1+ASA group, production of nitric oxide was decreased as
compared to the 4T1 group (280.2±83.2 AU�mg-1 of tissue vs 485.8±170.4 AU�mg-1 of tissue,
respectively, P = 0.0141) (Fig 6A). In the plasma, NO2
- concentration was lower in ASA-
treated mice compared to the 4T1 untreated group (0.068±0.039 μM vs 0.126±0.064 μM,
respectively, P = 0.0463) (Fig 6B), whereas NO3
- concentration was elevated in the 4T1+ASA
group as compared to the 4T1 control group (18.62±5.8 μM vs 11.68±2.3 μM, respectively,
P = 0.0075) (Fig 6C).
Fig 1. TXB2 production in ex vivo blood assay. Data are presented as mean ± SD. TXB2 (the stable product of TXA2
hydrolysis) concentration after stirring of blood samples ex vivo was measured by LC-MS/MS (A) as described in
Materials and Methods. For comparison, basal TXB2 concentration in plasma (B) was measured using ELISA kits and
the concentration of TXB2 metabolite 2,3-dinor-TXB2 in urine (C) was determined by LC-MS/MS. The data were
analysed with an unpaired two-sided T-test based on their normality of distribution (Shapiro-Wilk test) and equality of
variances (F test). In the case of (B), an unpaired T-test with Welch’s correction was used because variances of the
groups were not equal. The symbol � denotes statistical significance between 4T1+ ASA vs 4T1 untreated mice at the
level of P�0.05.
https://doi.org/10.1371/journal.pone.0230520.g001
PLOS ONE Aspirin affects late phase of mouse breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0230520 April 6, 2020 8 / 19
Effects of long-term ASA treatment on GSH and GSSG concentration in
circulating RBC of breast cancer-bearing mice
The concentration of reduced glutathione (GSH) was lower in RBC isolated from the 4T1+ASA
group in comparison with the control 4T1 group (1,533.0±184.9 μM vs 1,984.0±96.5 μM,
Fig 2. Eicosanoid production in ex vivo blood assay. The data are presented as median and IQR; for values<LOQ, the limit value of the method was used.
After euthanasia of 4T1+ASA and control 4T1 mice, blood samples were stimulated (stirring) for 1 h as described in Materials and Methods. Subsequently,
plasma was used for LC-MS/MS quantification of the panel of eicosanoid production: 6-keto PGF1α (6-keto-prostaglandin F1α; stable metabolite of
prostacyclin (PGI2) (A), PGE2 (prostaglandin E2) (B), PGD2 (prostaglandin D2) (C), PGF2α (prostaglandin F2α) (D), 8,9-EET (E), 11,12-EET (F), 14,15-EET
(G) (8,9-, 11,12-, and 14, 15-epoxyeicosatrienoic acids), 5-HETE (H), 12-HETE (I), 15-HETE (J), 19-HETE (K) and 20-HETE (L) (5-, 12-, 15-, 19- and
20-hydroxyeicosatetraenoic acids). The data were analysed with an unpaired two-sided T test (A, D, H, I, J, K, L) or non-parametric Mann-Whitney test (B,
C,E,F,G) based on their normality of distribution (Shapiro-Wilk normality test) and equality of variances (F test). Symbol � denotes statistical significance
between 4T1+ASA1 mice and 4T1 untreated animals at the level of P�0.05 (�), P�0.01 (��) and P�0.001 (���).
https://doi.org/10.1371/journal.pone.0230520.g002
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Fig 3. Platelet reactivity to ADP and thrombin. The data are presented as the mean ± SD (E, F) or the median and
IQR (A-D and G, H). Platelet basal as well as ADP and thrombin-stimulated surface antigen exposure was measured as
described in Materials and Methods. The symbol � indicates statistically significant difference between basal and ADP
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respectively, P<0.0001) (Fig 6D). In turn, the concentration of the oxidised form of glutathione
was elevated in breast cancer-bearing mice treated with ASA compared to the 4T1 group (29.5
±6.5 μM vs 22.5±2.6 μM, respectively, P = 0.0136) (Fig 6E).
Discussion
Acetylsalicylic acid (ASA, aspirin), already attracted attention several decades ago with respect
to its anti-cancer/anti-metastatic properties [25]. These anti-metastatic effects of low-dose
ASA (�100 mg in humans) can be attributed to the inhibition of COX-1/thromboxane A2
(TXA2) pathway in platelets [2]. Indeed, platelet COX-1 -derived TXA2 has been recently
or thrombin-stimulated platelets at the level of P�0.05 (�), P�0.01 (��) and P�0.001 (���), respectively. The data were
analysed with parametric One-Way ANOVA followed by Tukey’s post-hoc test or non-parametric Kruskall-Wallis test
followed by Dunn’s multiple comparison test based on the normality of distribution (Kolmogorov-Smirnov test) and
equality of variances (Barlett’s test).
https://doi.org/10.1371/journal.pone.0230520.g003
Table 1. Blood count and pulmonary metastasis in breast cancer-bearing mice.
Parameter Experimental groups
4T1 4T1+ASA
No of pulmonary metastases 36; 27–74 (n = 9) 55; 29–133 (n = 9)
Relative pulmonary metastatic area [%] 9.8±11.5 (n = 9) 16.9±15.1 (n = 9)
Primary tumor weight [% of BW] 9.4±4.8 (n = 22) 11.1±5.5 (n = 23)
Lung weight [% of BW] 1.2; 0.9–1.5 (n = 22) 1.7; 1.2–2.3 (n = 23)�
Airness of lungs [%] 44.4; 33.9–48.6 (n = 90) 32.5; 26.1–56.3 (n = 90)���
Nuclei area in the lungs [%] 28.0; 25.3–31.8 (n = 90) 29.3; 25.9–32.9 (n = 90)�
WBC [K�μl-1] 276.7; 154.3–385.1 (n = 13) 348.4; 270.0–468.2 (n = 13)
GRA [K�μl-1] 128.7±54.1 (n = 12) 220.7±104.2� (n = 14)
ANC [K�μl-1] 136239.0±86715.0 (n = 13) 309004.0±226538.0� (n = 14)
LYM [K�μl-1] 89.5±61.1 (n = 13) 73.0±35.2 (n = 14)
ALC [K�μl-1] 86573±64807 (n = 13) 103812±78990 (n = 14)
NLR [AU] 1.5; 1.3–2.2 (n = 12) 3.2; 2.2–4.0 (n = 14)��
Circulating RBC [M�μl-1] 9.0±0.6 (n = 13) 9.1±0.7 (n = 14)
HGB [g�dl-1] 14.3±0.9 (n = 13) 14.4±1.1 (13)
PLT [K�μl-1] 812.3±124.9 (n = 13) 1026.0±203.5 (n = 13) ��
Data are presented as the mean ± SD or the median and IQR (interquartile range). Low-dose aspirin was
administered to mice starting seven days prior to orthotopic inoculation of 4T1 breast cancer cells (4T1+ASA) at a
dose of ~ 12 mg per 1 kg of body weight per 24 h and continued until the 5th terminal week of the disease. At that
time, mice from 4T1-injected group and the 4T1-injected group treated with ASA were euthanised; blood samples
were collected to measure blood count (WBC, GRA, ANC (also known as absolute granulocyte count AGC: WBC x
%GRA), LYM, ALC-absolute lymphocyte count (WBC x %LYM); NLR-absolute neutrophil/absolute lymphocyte
ratio; RBC, HGB, PLT). Primary tumour and lung weight was presented as percentage of body weight (% of BW).
Lungs were excised, weighed, fixed in formalin, cut into lobes and visible metastatic nodules were counted.
Subsequently, lung lobes were paraffin-embedded, cut into slices and stained with H&E to measure the relative area
of pulmonary metastases. Airness of the lungs and lung nuclei area were measured as described in Materials and
Methods and presented as the % of the lung cross-section. Symbol � denotes statistical significance between 4T1 and
4T1+ ASA mice at the level of P�0.05 (�), P�0.01 (��), P�0.001 (���). Some data sets were Box-Cox transformed.
Based on the normality of distribution assessed with a Shapiro-Wilk normality test, equality of variances was assessed
with an F test and the variable scale, and data were analysed with a two-sided unpaired T-test or non-parametric
Mann-Whitney test.
https://doi.org/10.1371/journal.pone.0230520.t001
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shown to play a central role in the early phase of intravascular metastasis in the models of
experimental metastasis and spontaneous metastasis in mice but not in the extravasation or
extravascular phases of metastasis [15]. Our study extended results of Lucotti et al. [15] with
regard to the effects of ASA on the late phase of metastasis in mice. Long-term treatment with
ASA at a low dose did not affect the number of pulmonary metastases in a murine orthotopic
model of 4T1 breast cancer in a previous report [15]. In our study, we confirmed lack of the
effect of ASA on number of metastasis, but, quite surprisingly, we found that long-term treat-
ment with ASA negatively affected the phenotype of late-phase breast cancer, evidenced by
decreased lung airness, higher G-CSF concentrations in the lung homogenates as well as
decreased local pulmonary and systemic NO bioavailability along with increased GSSG/lower
GSH concentrations in RBC and some unfavourable changes in eicosanoid generation in the
blood of mice.
Undoubtedly, it was the most intriguing finding of this study to discover that lungs of breast
cancer-bearing mice receiving long-term treatment with ASA were more infiltrated by inflam-
matory cells when compared with control 4T1 mice that did not receive ASA (please compare
nuclei area in the lungs in the Table 1). Concomitantly, lungs of mice bearing breast cancer
subjected to long-term treatment with ASA displayed reduced airness and increased weight
(Table 1). More pronounced infiltration of lung parenchyma by inflammatory cells in breast
cancer-bearing mice receiving long-term treatment with ASA was also accompanied by
increased concentration of serotonin in their lung homogenates (Fig 5B) indicating a more
pro-inflammatory environment as reported by [24]. Additionally, in the lungs (but not in the
plasma) of breast cancer-bearing mice subjected to long-term treatment with ASA, G-CSF
production was higher (please compare Fig 5A and 5C). The cytokine G-CSF is known to
increase neutrophil survival, potentiate their responses to chemotactic signals [26] and
increase immunosuppression due to the possible augmented accumulation of Myeloid-
Derived Suppressor Cells (MDSCs) [27, 28], observations which are in accordance with the
suggestion that ASA may increase immunotolerance in BALB/c mice [29]. Additionally, treat-
ment with ASA as well as other NSAIDs was shown to potentiate recruitment of haematopoie-
tic stem cells (HSCs) from bone marrow in mice in the presence of G-CSF [30]. More
prominent inflammation of pulmonary parenchyma of breast cancer-bearing mice receiving
long-term ASA treatment was also reflected by compromised NO production in the lungs (Fig
Fig 4. Representative lung histological sections showing pulmonary metastasis in 4T1 and 4T1+ ASA groups of
mice. Lung slices were stained with hematoxylin and eosin (H&E) to visualise pulmonary metastasis in untreated 4T1
and ASA-treated (4T1+ASA) groups of mice and scanned with a BX51 microscope equipped with the virtual
microscopy system dotSlide (objective magnification 10x; Olympus, Japan). The representative images for 4T1 and
4T1+ASA mice are shown in (A) and (B), respectively, and pulmonary metastases were indicated with the dotted line.
Scale bar represents 2 mm.
https://doi.org/10.1371/journal.pone.0230520.g004
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6A) and systemic reduction of NO bioavailability as evidenced by lower NO2
- concentration in
the plasma (Fig 6B). Given the fact, that NO-dependent function represents key element con-
trolling cancer cell extravasation in the targeted organ [16, 31] and regulates endothelial per-
meability in vitro [32] and in vivo [33], these results underscore negative influence of long-
term ASA administration to breast cancer-bearing mice on endothelial barrier and NO-depen-
dent vasoprotective mechanisms. Simultaneously with NO deficiency, in circulating RBCs the
concentration of reduced glutathione (GSH) was lower (Fig 6D), and the concentration of its
oxidised counterpart (GSSG) was higher (Fig 6E). These data indicated more pronounced sys-
temic oxidative stress in ASA-treated breast cancer-bearing mice compatible with a NO-defi-
ciency state.
Negative effects of long-term ASA administration to breast cancer-bearing mice shown in
our work (however without effects on number of pulmonary metastasis and the size of primary
tumours) stay in contrast with the numerous reports on anti-cancer/anti-metastatic or, at
least, not harmful effects of ASA on cancer progression but seem consistent with recent report
Fig 5. G-CSF and serotonin concentration in lungs and plasma. Data are presented as mean ± SD. ASA was administered to mice starting seven days before
orthotopic inoculation of 4T1 breast cancer cells (4T1+ASA) at a dose of ~ 12 mg per 1 kg of body weight per 24 h and was continued until the 5th terminal week
of the disease. At that time, mice from both 4T1+ASA and 4T1 control groups were euthanised, and lungs were isolated for measurement of G-CSF (Granulocyte
Colony Stimulating Factor) (A) and serotonin (B) concentrations as well as G-CSF (C) and serotonin (D) concentrations in the plasma as described in Materials
and Methods. The data were analysed with a parametric two-sided T-test based on their normality of distribution (Shapiro-Wilk test) and equality of variances (F
test). In the case of (D), an unpaired T-test with Welch’s correction was used due to the fact that variances of the groups were not equal. The symbols � and ��
denote statistical significance between 4T1+ASA vs 4T1 mice at the level of P�0.05 and P�0.01, respectively.
https://doi.org/10.1371/journal.pone.0230520.g005
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Fig 6. NO production in lungs, systemic NO bioavailability and oxidative status of RBC. Data are presented as the mean ± SD. Lungs of 4T1
+ASA and 4T1 mice were collected to measure production of NO with Fe(DETC)2 (A), whereas systemic NO bioavailability was assessed in the
plasma by means of the concentration of NO2
- (B) and NO3
- (C). Concentration of GSH (D) and GSSG (E) was measured in RBC of breast cancer-
bearing mice treated (4T1+ASA) or not (4T1) with ASA as described in Materials and Methods. Data were analysed using an unpaired two-sided T-
test. Normality of distribution and equality of variances were tested with both Shapiro-Wilk and F tests, respectively, and in the case of (C) and (E),
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showing that long-term administration of low-dose aspirin to healthy elderly people increased
the number of cancer-related deaths [8].
Previously, Maity et al., [34]) demonstrated that ASA prevented breast tumour cell growth
in vitro, tumour growth in a nude mice xenograft model and reduced self-renewal capacity
and growth of breast tumour-initiating cells. ASA also relieved the metastatic burden to
regional lymph nodes in an orthotopic model of lung cancer [35] and compromised the num-
ber of secondary tumours after intravenous injection of cancer cells [15, 36]. Furthermore, in a
murine model of colorectal cancer (HT29), 20 mg�kg-1 of aspirin administered four days
before and for one week after cancer cell intravascular injection prevented an increase in the
rate of pulmonary metastasis in mice injected with cancer cells previously co-cultured with
platelets. In these experimental conditions, ASA profoundly inhibited TXB2 concentration in
serum and lowered urinary levels of 2,3-dinor-TXB2 (a major enzymatic metabolite of TXB2)
without inhibiting systemic PGI2 generation [37], suggesting that the anti-metastatic effect of
ASA could be due to inhibition of platelet-derived TXA2. In this report, the authors attributed
ASA effects also to the inhibition of PGE2-dependent mechanisms and platelet-tumour cell
interactions. Interestingly, in this study, ASA also did not lower the number of metastasis as
compared to mice injected with colon cancer cells alone although lung airness of ASA-treated
mice was compromised to a large extent (please see Fig 1A in [37]), similarly as in the present
study (Table 1). In fact, higher doses of ASA compared to the one used in our study were
required to compromise metastasis in mice, as shown in a recent study by Lucotti et al. [15],
and their effectiveness was similar to other pharmacological agents inhibiting COX-1/TXA2
pathway in platelets [15]. Most importantly, these anti-metastatic effects of ASA were seen
only when applied in the early phase during intravascular metastatic niche formation, but
could not be recapitulated in the extravasation or extravascular phases of metastasis, clearly
suggesting that the efficacy of ASA to inhibit metastasis was limited to short-term intravascular
phase of metastasis.
In our study, we used low-dose ASA (12 mg�kg-1 of body weight per day equivalent to ~100
mg per day in humans [1]) for long-term treatment to achieve selective inhibition of COX-
1-dependent thromboxane A2 generation in platelets without inhibition of COX-1 and COX-2
elsewhere. The treatment with 12 mg�kg-1 of ASA decreased platelet-dependent TXB2 genera-
tion in breast cancer-bearing mice in the ex vivo assay of stirred blood (Fig 1A) that allows for
highly sensitive assessment of platelet activation, as reported by us previously [21]. However,
the inhibitory effect of ASA on TXB2 production and platelet reactivity was not detected in
other assays (Figs 1B, 1C and 3). Moreover, ASA treatment also affected production of other
eicosanoids in the stirred blood because it decreased generation of EETs (known to exert anti-
inflammatory and vasoprotective effects [38]) (Fig 2F and 2G), and increased production of
20-HETE (known to promote progression of malignant diseases [39]) and 19-HETE, as shown
in Fig 2K and 2L, respectively, without an effect on prostaglandin production (Fig 2A–2D).
However, the latter result does not preclude that COX-1 or COX-2 activity could have been
locally affected in some organs by ASA treatment because even low-dose ASA could inhibit
COX-2 activity in urine as measured by PGE2-M (please see S2 Fig in [15]). Accordingly, long-
term ASA treatment in mice may exert effects on extra-platelet COX that could have contrib-
uted to the detrimental effects of ASA observed in our study. For example, inhibition of COX-
dependent PGE2 production by ASA in the gut results in gut barrier dysfunction [40, 41] due
to dysregulation of the immune response [42]. Similarly, pro-inflammatory effects of ASA
an unpaired T-test with Welch’s correction was used because variances of the groups were not equal. Symbol � denotes statistical significance
between 4T1+ASA vs 4T1 mice at the level of P�0.05 (�), P�0.01 (��) and P�0.001 (���).
https://doi.org/10.1371/journal.pone.0230520.g006
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could be ascribed to bone marrow where recruitment of haematopoietic stem cells (HSCs) is
regulated by COX [30]. Finally, given the recent discovery of the role of platelets in non-classi-
cal haemostasis, negative effects of long-term treatment with low-dose ASA could be attributed
to impaired endothelial barrier constantly supported by platelets by various mechanisms par-
ticularly in the lungs [43–45].
Concluding, ASA administration to cancer-bearing mice induced some pro-inflammatory
changes in the profile of eicosanoids compatible with some reports on COX inhibitors [30, 42,
46–48], but in contrast with the general view of ASA as an anti-inflammatory agent inhibiting
TXA2, 11-HETE and 15-HETE production [49, 50] and stimulating the generation of anti-
inflammatory proresolvines (AT-SPMs), such as resolvins (AT-RvDs) and lipoxins (AT-LXs)
[50]. Given our findings and those of others, aspirin seems to induce a more complex pattern
of changes in the eicosanoid profile in mice as previously thought [50], and, therefore, the
effects of low-dose ASA in vivo need to be extensively re-evaluated, in particular in inflamma-
tory conditions. These studies should be focused not only on a number of new lipid mediators
recently discovered to be affected by aspirin, but also should include COX-independent effects
of ASA linked to acetylation of other proteins, RNA and ASA metabolites [51] that may play a
role in mice metabolising ASA much faster than humans. To summarise, in our study, the
effects of low-dose ASA observed in mice were not equivalent to those in humans because 100
mg per day of ASA in humans inhibits quite selectively COX-1 in platelets and is considered a
relatively selective anti-platelet treatment, whereas an equivalent dose in mice (12 mg per kg of
body weight) only mildly inhibited the COX-1/TXA2 pathway in platelets of breast cancer-
bearing mice (Fig 1). Furthermore, such a dose of ASA given to mice also altered the genera-
tion of other eicosanoids in cancer-bearing (Fig 2) mice including the inhibition of COX-
derived prostanoids far beyond platelet COX-1, inhibition of EET pathway and stimulation of
HETE production (5, 19 and 20-HETE) in the blood. To conclude, low-dose aspirin is not a
selective murine platelet COX-1/TXA2 pathway inhibitor. Altogether, our results demonstrate
negative effects of long-term treatment with ASA in a murine orthotopic model of 4T1 breast
cancer. Whether these findings could be ascribed to the weakening of endothelial barrier integ-
rity supported by platelets [43, 52] or to other mechanisms remains to be established.
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